|
|
 |
|
Viewing report
|
|
|
|
Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health
Spectra Intelligence, May 2011, Pages: 67
Provides analysis of over ten key marketed products and indentifies over 40 R&D candidates in preclinical to clinical stages of development.
The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.
In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.
The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.
Key findings of the report include
- The worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.
- Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.
- Currently, there are over 40 pipeline candidates for female and male contraception.
- The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.
- Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.
- Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.
- The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.
Questions answered by this report include:
- Which contraceptives and infertility drugs are the current and potential future market leaders
- What impact new drug approvals will have on the reproductive medicine drug market
- Which premarket drugs are identified as high-value products
- Which companies are developing hormonal contraceptives and infertility drugs
- Sales predictions to 2018 for leading contraceptives and infertility drugs
- How will newcomers affect the product positioning of market leaders
- What are niche market opportunities in reproductive medicine
- What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies
- How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders
- Which molecules and compounds are main R&D clusters in reproductive medicine
Research Methodology
The contents of this report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:
- Company information
- Scientific periodicals
- Personal communication
- Product information
- Trade press articles
- Market analyst data
- News releases
- Public information datasets
- Internet-based research
- Conference proceedings
- Library research
- Medical/pharma associations
|
|
|
|
